Physician profile
Steven Hahn
NPI 1417925801
$4,063.78
in general payments reported to CMS, 2019-2025
25 companies · $999 in 2025
The $999 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $240 · 2021: $364 · 2022: $690 · 2023: $491 · 2024: $816 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,306.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $820.73 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Abbvie INC. | $574.29 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.57 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Intercept Pharmaceuticals, INC. | $393.37 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $249.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $228.24 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $203.11 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $168.34 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $122.41 | 2019-2020 | |
| Ardelyx, INC. | $96.96 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $94.14 | 2025 | |
| Daiichi Sankyo INC. | $70.52 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $63.84 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $62.66 | 2025 | Dupixent |
| Redhill Biopharma INC. | $59.21 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $58.64 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $50.89 | 2019-2020 | |
| Pfizer INC. | $47.45 | 2024 | |
| Intra-Sana Laboratories | $32.34 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Novo Nordisk INC | $28.79 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $18.36 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $17.38 | 2020 | |
| Alfasigma USA, INC. | $16.32 | 2020 | |
| Evoke Pharma, INC. | $13.68 | 2020 | |
| Merck Sharp & Dohme LLC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.